兴奋剂
便秘
化学
药理学
受体
药代动力学
选择性
口服
结构-活动关系
铅化合物
部分激动剂
同源建模
肽
内科学
生物信息学
化学合成
药物发现
虚拟筛选
对接(动物)
作者
Aolong Shang,Shiyu Yan,李成浩 Li Chenghao,Yuzhu Wu,Ning Tian,Siyi Pan,Hong Liu,Dehua Yang,Jiang Wang
标识
DOI:10.1021/acs.jmedchem.6c02509
摘要
The relaxin family peptide receptor 4 (RXFP4) is a promising therapeutic target for constipation owing to its critical role in regulating gastrointestinal motility. However, the development of selective small-molecule RXFP4 agonists remains challenging because of the high structural homology between RXFP4 and RXFP3 and the difficulty of achieving gut-restricted exposure. Herein, guided by the cryo-electron microscopy structure of RXFP4, we report the structure-guided design and optimization of a novel series of tetrahydroisoquinoline-based RXFP4 agonists. Structure-activity relationship studies identified compound 44 as a potent RXFP4 agonist with excellent selectivity over RXFP3 and a gut-restricted pharmacokinetic profile with an approximately 500-fold ileum-to-plasma exposure ratio. In a loperamide-induced constipation mouse model, oral administration of compound 44 significantly enhanced colorectal propulsion and alleviated constipation-related symptoms. Collectively, this work establishes a structure-guided strategy for optimizing receptor subtype selectivity and gut-restricted exposure, providing a promising lead and a framework for the development of RXFP4-targeted therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI